View ValuationInstituto Rosenbusch 将来の成長Future 基準チェック /06現在、 Instituto Rosenbuschの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長13.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 21Instituto Rosenbusch S.A., Annual General Meeting, May 13, 2026Instituto Rosenbusch S.A., Annual General Meeting, May 13, 2026. Location: san jose 1481, buenos aires ArgentinaNew Risk • Apr 12New major risk - Negative shareholders equityThe company has negative equity. Total equity: -AR$526m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Negative equity (-AR$526m). Earnings have declined by 57% per year over the past 5 years. Market cap is less than US$10m (AR$6.98b market cap, or US$5.10m). Minor Risk Revenue is less than US$5m (AR$6.4b revenue, or US$4.7m).Reported Earnings • Jan 16Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: AR$1.75b (down 24% from 3Q 2024). Net loss: AR$1.39b (loss widened 452% from 3Q 2024).New Risk • Nov 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Argentinean stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 29% per year over the past 5 years. Market cap is less than US$10m (AR$13.9b market cap, or US$9.78m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AR$5.0b revenue, or US$3.5m).Reported Earnings • Sep 28Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: AR$1.41b (down 36% from 2Q 2024). Net loss: AR$1.27b (loss widened 319% from 2Q 2024).New Risk • Jul 10New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 10% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (AR$5.91b market cap, or US$4.69m).New Risk • Jul 07New major risk - Revenue and earnings growthEarnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (AR$5.99b market cap, or US$4.72m). Minor Risk Revenue is less than US$5m (AR$6.3b revenue, or US$5.0m).Buy Or Sell Opportunity • Jun 04Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 88% to AR$207. The fair value is estimated to be AR$161, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last 3 years. Meanwhile, the company became loss making.New Risk • May 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Argentinean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (AR$5.04b market cap, or US$4.24m). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).Buy Or Sell Opportunity • Apr 10Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to AR$91.60. The fair value is estimated to be AR$120, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Meanwhile, the company became loss making.New Risk • Mar 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (AR$4.68b market cap, or US$4.40m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (AR$5.1b revenue, or US$4.8m).New Risk • Dec 10New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: AR$5.1b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (AR$4.86b market cap, or US$4.78m). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (AR$5.1b revenue, or US$5.0m).Valuation Update With 7 Day Price Move • Oct 24Investor sentiment improves as stock rises 18%After last week's 18% share price gain to AR$106, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 18x in the Pharmaceuticals industry in South America. Total returns to shareholders of 912% over the past three years.Valuation Update With 7 Day Price Move • Sep 20Investor sentiment improves as stock rises 25%After last week's 25% share price gain to AR$120, the stock trades at a trailing P/E ratio of 5.1x. Average trailing P/E is 18x in the Pharmaceuticals industry in South America. Total returns to shareholders of 941% over the past three years.Valuation Update With 7 Day Price Move • Sep 06Investor sentiment improves as stock rises 20%After last week's 20% share price gain to AR$101, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in South America. Total returns to shareholders of 794% over the past three years.Reported Earnings • Aug 22Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: AR$2.20b (up 248% from 2Q 2023). Net loss: AR$302.3m (loss widened 262% from 2Q 2023).Reported Earnings • May 24First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: AR$1.96b (up 479% from 1Q 2023). Net income: AR$317.7m (up AR$348.2m from 1Q 2023). Profit margin: 16% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has increased by 127% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • May 06Investor sentiment improves as stock rises 19%After last week's 19% share price gain to AR$106, the stock trades at a trailing P/E ratio of 8x. Average trailing P/E is 24x in the Pharmaceuticals industry globally. Total returns to shareholders of 1,052% over the past three years.Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 33%After last week's 33% share price gain to AR$117, the stock trades at a trailing P/E ratio of 59.8x. Average trailing P/E is 23x in the Pharmaceuticals industry globally. Total returns to shareholders of 1,077% over the past three years.Valuation Update With 7 Day Price Move • Mar 06Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to AR$91.10, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 23x in the Pharmaceuticals industry globally. Total returns to shareholders of 759% over the past three years.New Risk • Mar 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Argentinean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.6% operating cash flow to total debt). Market cap is less than US$10m (AR$4.74b market cap, or US$5.62m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (AR$1.2b revenue, or US$1.4m).Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improves as stock rises 28%After last week's 28% share price gain to AR$130, the stock trades at a trailing P/E ratio of 66.6x. Average trailing P/E is 23x in the Pharmaceuticals industry globally. Total returns to shareholders of 1,080% over the past three years.New Risk • Feb 11New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 172% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.6% operating cash flow to total debt). Market cap is less than US$10m (AR$4.43b market cap, or US$5.33m). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (AR$1.2b revenue, or US$1.4m).Valuation Update With 7 Day Price Move • Jan 25Investor sentiment improves as stock rises 43%After last week's 43% share price gain to AR$99.80, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 23x in the Pharmaceuticals industry globally. Total returns to shareholders of 768% over the past three years.New Risk • Nov 29New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.02x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Market cap is less than US$10m (AR$2.49b market cap, or US$6.92m).New Risk • Sep 16New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.0% per year over the past 5 years. Market cap is less than US$10m (AR$1.26b market cap, or US$3.62m). Minor Risk Revenue is less than US$5m (AR$1.3b revenue, or US$3.6m).Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improves as stock rises 18%After last week's 18% share price gain to AR$24.70, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 24x in the Pharmaceuticals industry globally. Total returns to shareholders of 184% over the past three years.Valuation Update With 7 Day Price Move • Jun 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to AR$20.85, the stock trades at a trailing P/E ratio of 19.5x. Average trailing P/E is 15x in the Pharmaceuticals industry in South America. Total returns to shareholders of 180% over the past three years.Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 22%After last week's 22% share price gain to AR$18.00, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 13x in the Pharmaceuticals industry in South America. Total returns to shareholders of 163% over the past three years.Is New 90 Day High Low • Mar 05New 90-day low: AR$10.00The company is down 12% from its price of AR$11.35 on 04 December 2020. The Argentinean market is down 15% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.Is New 90 Day High Low • Jan 19New 90-day high: AR$11.85The company is up 45% from its price of AR$8.20 on 21 October 2020. The Argentinean market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.Is New 90 Day High Low • Nov 20New 90-day high: AR$11.50The company is up 29% from its price of AR$8.89 on 21 August 2020. The Argentinean market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.Is New 90 Day High Low • Oct 31New 90-day high: AR$10.60The company is up 15% from its price of AR$9.25 on 31 July 2020. The Argentinean market is down 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 20% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Instituto Rosenbusch は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BASE:ROSE - アナリストの将来予測と過去の財務データ ( )ARS Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20256,404-4,598398410N/A9/30/20254,043-4,351-670-663N/A6/30/20255,006-3,297-602-594N/A3/31/20256,336-2,503209219N/A12/31/202410,886-1,864707720N/A9/30/202412,681466789855N/A6/30/202412,0521,6719411,000N/A3/31/202411,6031,8391,0551,150N/A12/31/20239,8601,226216331N/A9/30/20237,933370218335N/A6/30/20236,787-52640177N/A3/31/20235,138-199-299N/A12/31/20224,276-2571153N/A9/30/20222,5505992119N/A6/30/20221,89219145155N/A3/31/20221,66829142149N/A12/31/20211,523-385458N/A9/30/20211,266-567377N/A6/30/20211,224-246568N/A3/31/20211,009-386063N/A12/31/2020843-266366N/A9/30/2020746-474852N/A6/30/2020662-636062N/A3/31/2020585-1142731N/A12/31/2019561-1214959N/A9/30/2019360-119N/A54N/A6/30/2019363-42N/A34N/A3/31/2019350-3N/A8N/A12/31/20182991N/A-22N/A9/30/2018481-17N/A-23N/A6/30/2018359-50N/A-23N/A3/31/2018293-53N/A-4N/A12/31/2017274-48N/A-4N/A9/30/201716311N/A0N/A6/30/201717411N/A7N/A3/31/201717111N/A13N/A12/31/201616710N/A16N/A9/30/20161869N/A-5N/A6/30/20161676N/A-12N/A3/31/20161501N/A-7N/A12/31/2015135-1N/A-9N/A9/30/2015107-10N/A5N/A6/30/2015109-1N/A16N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ROSEの予測収益成長が 貯蓄率 ( 8.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ROSEの収益がAR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ROSEの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ROSEの収益がAR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ROSEの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ROSEの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 05:00終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Instituto Rosenbusch S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 21Instituto Rosenbusch S.A., Annual General Meeting, May 13, 2026Instituto Rosenbusch S.A., Annual General Meeting, May 13, 2026. Location: san jose 1481, buenos aires Argentina
New Risk • Apr 12New major risk - Negative shareholders equityThe company has negative equity. Total equity: -AR$526m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Negative equity (-AR$526m). Earnings have declined by 57% per year over the past 5 years. Market cap is less than US$10m (AR$6.98b market cap, or US$5.10m). Minor Risk Revenue is less than US$5m (AR$6.4b revenue, or US$4.7m).
Reported Earnings • Jan 16Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: AR$1.75b (down 24% from 3Q 2024). Net loss: AR$1.39b (loss widened 452% from 3Q 2024).
New Risk • Nov 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Argentinean stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 29% per year over the past 5 years. Market cap is less than US$10m (AR$13.9b market cap, or US$9.78m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AR$5.0b revenue, or US$3.5m).
Reported Earnings • Sep 28Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: AR$1.41b (down 36% from 2Q 2024). Net loss: AR$1.27b (loss widened 319% from 2Q 2024).
New Risk • Jul 10New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 10% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (10% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (AR$5.91b market cap, or US$4.69m).
New Risk • Jul 07New major risk - Revenue and earnings growthEarnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (AR$5.99b market cap, or US$4.72m). Minor Risk Revenue is less than US$5m (AR$6.3b revenue, or US$5.0m).
Buy Or Sell Opportunity • Jun 04Now 28% overvalued after recent price riseOver the last 90 days, the stock has risen 88% to AR$207. The fair value is estimated to be AR$161, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last 3 years. Meanwhile, the company became loss making.
New Risk • May 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Argentinean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (AR$5.04b market cap, or US$4.24m). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
Buy Or Sell Opportunity • Apr 10Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to AR$91.60. The fair value is estimated to be AR$120, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 42% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Mar 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (AR$4.68b market cap, or US$4.40m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Large one-off items impacting financial results. Revenue is less than US$5m (AR$5.1b revenue, or US$4.8m).
New Risk • Dec 10New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: AR$5.1b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (AR$4.86b market cap, or US$4.78m). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (AR$5.1b revenue, or US$5.0m).
Valuation Update With 7 Day Price Move • Oct 24Investor sentiment improves as stock rises 18%After last week's 18% share price gain to AR$106, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 18x in the Pharmaceuticals industry in South America. Total returns to shareholders of 912% over the past three years.
Valuation Update With 7 Day Price Move • Sep 20Investor sentiment improves as stock rises 25%After last week's 25% share price gain to AR$120, the stock trades at a trailing P/E ratio of 5.1x. Average trailing P/E is 18x in the Pharmaceuticals industry in South America. Total returns to shareholders of 941% over the past three years.
Valuation Update With 7 Day Price Move • Sep 06Investor sentiment improves as stock rises 20%After last week's 20% share price gain to AR$101, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in South America. Total returns to shareholders of 794% over the past three years.
Reported Earnings • Aug 22Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: AR$2.20b (up 248% from 2Q 2023). Net loss: AR$302.3m (loss widened 262% from 2Q 2023).
Reported Earnings • May 24First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: AR$1.96b (up 479% from 1Q 2023). Net income: AR$317.7m (up AR$348.2m from 1Q 2023). Profit margin: 16% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has increased by 127% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • May 06Investor sentiment improves as stock rises 19%After last week's 19% share price gain to AR$106, the stock trades at a trailing P/E ratio of 8x. Average trailing P/E is 24x in the Pharmaceuticals industry globally. Total returns to shareholders of 1,052% over the past three years.
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 33%After last week's 33% share price gain to AR$117, the stock trades at a trailing P/E ratio of 59.8x. Average trailing P/E is 23x in the Pharmaceuticals industry globally. Total returns to shareholders of 1,077% over the past three years.
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to AR$91.10, the stock trades at a trailing P/E ratio of 46.8x. Average trailing P/E is 23x in the Pharmaceuticals industry globally. Total returns to shareholders of 759% over the past three years.
New Risk • Mar 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Argentinean stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.6% operating cash flow to total debt). Market cap is less than US$10m (AR$4.74b market cap, or US$5.62m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Revenue is less than US$5m (AR$1.2b revenue, or US$1.4m).
Valuation Update With 7 Day Price Move • Feb 15Investor sentiment improves as stock rises 28%After last week's 28% share price gain to AR$130, the stock trades at a trailing P/E ratio of 66.6x. Average trailing P/E is 23x in the Pharmaceuticals industry globally. Total returns to shareholders of 1,080% over the past three years.
New Risk • Feb 11New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 172% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.6% operating cash flow to total debt). Market cap is less than US$10m (AR$4.43b market cap, or US$5.33m). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (AR$1.2b revenue, or US$1.4m).
Valuation Update With 7 Day Price Move • Jan 25Investor sentiment improves as stock rises 43%After last week's 43% share price gain to AR$99.80, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 23x in the Pharmaceuticals industry globally. Total returns to shareholders of 768% over the past three years.
New Risk • Nov 29New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.02x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.02x net interest cover). Market cap is less than US$10m (AR$2.49b market cap, or US$6.92m).
New Risk • Sep 16New major risk - Revenue and earnings growthEarnings have declined by 1.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.0% per year over the past 5 years. Market cap is less than US$10m (AR$1.26b market cap, or US$3.62m). Minor Risk Revenue is less than US$5m (AR$1.3b revenue, or US$3.6m).
Valuation Update With 7 Day Price Move • Aug 17Investor sentiment improves as stock rises 18%After last week's 18% share price gain to AR$24.70, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 24x in the Pharmaceuticals industry globally. Total returns to shareholders of 184% over the past three years.
Valuation Update With 7 Day Price Move • Jun 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to AR$20.85, the stock trades at a trailing P/E ratio of 19.5x. Average trailing P/E is 15x in the Pharmaceuticals industry in South America. Total returns to shareholders of 180% over the past three years.
Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 22%After last week's 22% share price gain to AR$18.00, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 13x in the Pharmaceuticals industry in South America. Total returns to shareholders of 163% over the past three years.
Is New 90 Day High Low • Mar 05New 90-day low: AR$10.00The company is down 12% from its price of AR$11.35 on 04 December 2020. The Argentinean market is down 15% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Jan 19New 90-day high: AR$11.85The company is up 45% from its price of AR$8.20 on 21 October 2020. The Argentinean market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 11% over the same period.
Is New 90 Day High Low • Nov 20New 90-day high: AR$11.50The company is up 29% from its price of AR$8.89 on 21 August 2020. The Argentinean market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 7.0% over the same period.
Is New 90 Day High Low • Oct 31New 90-day high: AR$10.60The company is up 15% from its price of AR$9.25 on 31 July 2020. The Argentinean market is down 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 20% over the same period.